Journal of the Formosan Medical Association
Volume 105, Issue 7 , Pages 588-593, 2006

Nonresponse to 18-month Lamivudine Monotherapy in Chronic Hepatitis B Patients with Dual Genotype B and C Infection and Acute Exacerbation

  • Jyh-Jou Chen

      Affiliations

    • Department of Internal Medicine, Chi Mei Hospital Liouying, Tainan, Taiwan
    • ,
  • Ling-Yu Tang

      Affiliations

    • Liver Research Unit, Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan
    • ,
  • Sun-Lung Tsai

      Affiliations

    • Liver Research Unit, Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Sun-Lung Tsai, Liver Research Unit, Department of Medical Research, Chi Mei Medical Center, 901, Chung Hwa Road, Yung Kang City, Tainan 710, Taiwan

Division of Hepatogastroenterology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan

Received 17 June 2005; received in revised form 28 July 2005; accepted 13 September 2005.

Article Outline

Molecular epidemiologic studies have indicated the possible existence of mixed infection of different hepatitis B virus (HBV) genotypes in chronic hepatitis B (CH-B) carriers, but the effect of dual HBV genotype B and C infection on the efficacy of lamivudine therapy remains unclear. We report four CH-B patients with dual HBV genotype B and C infection and acute exacerbation who received lamivudine monotherapy for about 18 months. None of them had achieved a sustained response at the end of the 18-month trial of treatment.

Key Words:  acute exacerbation , chronic hepatitis B , dual genotype infection , hepatitis B virus , lamivudine therapy , sustained response

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Lai CL , Chien RH , Leung NWY , et al.   A one-year trial of lamivudine for chronic hepatitis B . N Engl J Med. . 1998;339:61–68
  2. Jarvis B , Faulds D . Lamivudine: a review of its therapeutic potential in chronic hepatitis B . Drugs . 1999;58:101–141
  3. Dienstag JL , Schiff ER , Wright TL , et al.   Lamivudine as initial treatment for chronic hepatitis B in the United States . N Engl J Med. . 1999;341:1256–1263
  4. Liaw YF , Leung NWY , Chang TT , et al.   Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B . Gastroenterology . 2000;119:172–180
  5. Jonas MM , Mizerski J , Badia IB , et al.   Clinical trial of lamivudine in children with chronic hepatitis B . N Engl J Med. . 2002;346:1706–1713
  6. Doong SL , Tsai CH , Schinazi RF , et al.   Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues . Proc Natl Acad Sci USA . 1991;88:8495–8499
  7. Dienstag JL , Perillo RP , Schiff ER , et al.   A preliminary trial of lamivudine for chronic hepatitis B infection . N Engl J Med. . 1995;333:1657–1661
  8. Mckenzie R , Fried MW , Sallie R , et al.   Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B . N Engl J Med. . 1995;333:1099–1105
  9. Liaw YF , Sung JJY , Chow WC , et al.   Lamivudine for patients with chronic hepatitis B and advanced liver disease . N Engl J Med. . 2004;351:1521–1531
  10. Dienstag JL , Goldin RD , Heathcote EJ , et al.   Histological outcome during long-term lamivudine therapy . Gastro-enterology . 2003;124:105–117
  11. Chang TT , Lai CL , Chien RN , et al.   Four years of lamivu-dine treatment in Chinese patients with chronic hepatitis B . J Gastroenterol Hepatol . 2004;19:1276–1282
  12. Liaw YF . Results of lamivudine trials in Asia . J Hepatol . 2003;39:S111–S115
  13. Chien RN , Yeh CT , Tsai SL , et al.   The determinants for sustained HBeAg response to lamivudine therapy . Hepatology . 2003;38:1267–1273
  14. Stuyver L , De Gendr S , Van Geyt C , et al.   A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness . J Gen Virol . 2000;81:67–74
  15. Arauz-Ruiz P , Norder H , Robertson BH , et al.   Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America . J Gen Virol . 2002;83:2059–2073
  16. Magnius LO , Norder H . Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene . Intervirology . 1995;38:24–34
  17. Usuda S , Okamoto H , Iwanari H , et al.   Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product . J Virol Methods . 1999;80:97–112
  18. Grandjacques C , Pradat P , Stuyver L , et al.   Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity . J Hepatol . 2000;33:430–439
  19. Chen BF , Chen PJ , Jow GM , et al.   High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users . J Med Virol . 2004;74:536–542
  20. Chen BF , Kao JH , Liu CJ , et al.   Genotypic dominance and novel recombinations in HBV genotype B and C co-infected intravenous drug users . J Med Virol . 2004;73:13–22
  21. Perrillo R . Acute flares in chronic hepatitis B. the natural and unnatural history of an immunologically mediated liver disease . Gastroenterology . 2001;20:1009–1022
  22. Tsai SL , Chen PJ , Lai MY , et al.   Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens . J Clin Invest . 1992;89:87–96
  23. Lindh M , Andersson AS , Gusdal A . Genotypes, nt1858 variants, and geographic origin of hepatitis B virus – large-scale analysis using a new genotyping method . J Infect Dis . 1997;175:1285–1293
  24. Okamoto H , Tsuda F , Sakugawa H , et al.   Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes . J Gen Virol . 1988;69:2575–2583
  25. Purcell RH . Hepatitis viruses: changing patterns of human disease . Proc Natl Acad Sci USA . 1994;91:2401–2405
  26. Kao JH , Chen PJ , Lai MY , et al.   Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B . Gastroenterology . 2000;118:554–559
  27. Sumi H , Yokosuka O , Seki S , et al.   Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease . Hepatology . 2003;37:19–26
  28. Yuen MF , Sablon E , Yuan HJ , et al.   Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications and hepatocellular carcinoma . Hepatology . 2003;37:562–567
  29. Kao JH , Wu NH , Chen PJ , et al.   Hepatitis B genotypes and the response to interferon therapy . J Hepatol . 2000;33:998–1002
  30. Kao JH , Wu NH , Chen PJ , et al.   Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers . Gastroenterology . 2003;124:327–334
  31. Kao JH , Liu CJ , Chen DS . Hepatitis B viral genotypes and lamivudine resistance . J Hepatol . 2002;36:303–304
  32. Yuen MF , Wong DK , Sablon E , et al.   Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine . Antivir Ther . 2003;8:531–534
  33. Kato H , Orito E , Gish RG , et al.   Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G . Hepatology . 2002;35:922–929

PII: S0929-6646(09)60155-8

doi:10.1016/S0929-6646(09)60155-8

Journal of the Formosan Medical Association
Volume 105, Issue 7 , Pages 588-593, 2006

Article Tools